CTRL Therapeutics is developing a polyclonal cell therapy that utilizes circulating T cells (cTRLs) extracted from a single blood draw to target solid tumors, which account for 90% of all cancers. This approach eliminates the need for invasive surgical procedures and simplifies the complexities associated with traditional solid tumor cell therapies.
Funding
$9.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors represent 90% of all cancers, yet have not benefited from cell therapy breakthroughs seen in blood cancers. Emerging treatments like TILs utilize exhausted cells from surgically removed cancer tissue, an invasive and complex process for patients, while TCR-based therapies lack a breadth of tumor-specific targets.
Solution
CTRL Therapeutics is developing a novel polyclonal cell therapy for solid tumors using circulating T cells (cTRLs) extracted from a single blood draw, eliminating the need for surgical tumor removal. Their proprietary IsoQore™ platform efficiently isolates millions of rare, tumor-reactive cTRLs from the bloodstream using novel markers. This approach simplifies cell therapy development, manufacturing, and administration, offering a less invasive and potentially more effective treatment option for solid tumors. The resulting cTRL-based therapy aims to overcome the limitations of existing solid tumor cell therapies by utilizing a naturally equipped and readily accessible source of tumor-fighting cells.
Target Audience
The primary target audience includes patients with solid tumors who are seeking less invasive and more effective treatment options, as well as oncologists and medical centers specializing in cell therapy.
Features
- Proprietary IsoQore™ cell-sorting platform for efficient isolation of cTRLs from a single blood draw.
- Polyclonal cTRL population targeting a broad range of tumor-specific antigens.
- Non-invasive cell source, eliminating the need for surgical tumor removal.
- Simplified manufacturing process compared to traditional TIL therapies.
- Potential for improved efficacy and reduced toxicity compared to TCR-based therapies.